Trial record 2 of 8 for:
eflapegrastim
Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy (NEUTHREE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05949333 |
Recruitment Status :
Recruiting
First Posted : July 18, 2023
Last Update Posted : February 23, 2024
|
Sponsor:
Eunseong Medical Foundation Good GANG-AN HOSPITAL
Collaborator:
Hanmi Pharmaceutical Company Limited
Information provided by (Responsible Party):
Changwan Jeon, Eunseong Medical Foundation Good GANG-AN HOSPITAL
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | January 2025 |
Estimated Study Completion Date : | July 2025 |
Publications:
Kaufman PA, Paroly W, Rinaldi D. Randomized double blind phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with docetaxel, doxorubicin and cyclophosphamide (TAC) in women with early stage and advanced breast cancer. Breast Cancer Res Treat 2004;88:S59.
Saven A, Schwartzberg L, Kaywin P, et al. Randomized, double-blind, phase 2, study evaluating same-day vs next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients. J ClinOncol2006;24:7570.